AqueSys, Inc., a medical device company that develops, manufactures, and internationally markets the XEN Gel Stent technology for treating glaucoma, today announced that it has secured $43.6 million in Series D financing. The round was led by a new undisclosed investor with participation from existing investors Accuitive Medical Ventures, The Carlyle Group, Longitude Capital, Rho Ventures, and SV Life Sciences.
AqueSys also announced it successfully completed enrollment of their first FDA IDE study, and has begun enrollment of their second FDA approved IDE study utilizing an additional XEN Gel Stent model. Furthermore, the company also recently initiated focused international commercialization.
“AqueSys is very pleased to raise this significant round of financing with a premier group of venture capital and private equity partners who share our vision to significantly improve the glaucoma treatment paradigm through highly effective, yet minimally invasive technology. Our XEN Gel Stent international trials have demonstrated the minimally invasive technology’s ability to safely and significantly lower intraocular pressure via the globally accepted gold standard mechanism of action (subconjunctival drainage). Our strong capitalization allows us to confidently look forward, and accelerate the execution and attainment of our clinical, regulatory, and commercial goals,” said Ron Bache, AqueSys, Inc. President and CEO.
Glaucoma is the world’s number two cause of blindness affecting more than 60 million people worldwide. It is estimated to be a $5 billion dollar annual market.
